Iopromide (Ultravist, BAY86-4877)
Iopromide (Ultravist, BAY86-4877) is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
No phase data available
Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Status
Recent Activity
A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions
Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid
A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting
Observational Study of Ultravist in Patients Requiring CECT
The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)
Clinical Trials (5)
A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions
Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid
A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting
Observational Study of Ultravist in Patients Requiring CECT
The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5